Stryker Logs Higher 4Q Profit On Sales Gains

Dow Jones

2 hours ago

By Amira McKee

Stryker posted higher profit in its fourth quarter, boosted by double-digit growth in medical and surgical equipment and neurotechnology sales.

The Portage, Mich.-based, medical supplies maker logged fourth-quarter profit of $849 million, or $2.20 per share, compared with $546 million, or $1.41 per share, a year earlier.

Adjusted earnings came in at $4.47 per share. Analysts polled by FactSet were expecting $4.06 per share.

Sales rose 11.4% to $7.17 billion, beating the $7.12 billion expected by Wall Street, according to FactSet. Organic sales increased 11% in the period, the company added.

MedSurg and neurotechnology sales increased 17.5% in the quarter to $4.6 billion, while orthopaedics sales grew 2.2% to $2.6 billion.

For the full year 2025, the company posted sales of $25.1 billion, up 11.2% from the year prior.

In 2026, Stryker expects full year organic net sales growth to be in the range of 8% to 9.5% and adjusted earnings to be in the range of $14.90 to $15.10 per share.

Analysts polled by FactSet are predicting 2026 adjusted earnings of $14.03 per share.

"Having surpassed $25 billion in revenue, we enter 2026 with significant momentum and are poised to continue delivering growth at the high end of MedTech," Chief Executive Officer Kevin A. Lobo said.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 29, 2026 16:50 ET (21:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2607054843"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607054843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607054843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 05:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607054843","market":"sg","top_or_hot":-1,"title":"Stryker Logs Higher 4Q Profit On Sales Gains","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Stryker posted higher profit in its fourth quarter, boosted by double-digit growth in medical and surgical equipment and neurotechnology sales. \n</p>\n<p>\n  The Portage, Mich.-based, medical supplies maker logged fourth-quarter profit of $849 million, or $2.20 per share, compared with $546 million, or $1.41 per share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $4.47 per share. Analysts polled by FactSet were expecting $4.06 per share. \n</p>\n<p>\n  Sales rose 11.4% to $7.17 billion, beating the $7.12 billion expected by Wall Street, according to FactSet. Organic sales increased 11% in the period, the company added. \n</p>\n<p>\n  MedSurg and neurotechnology sales increased 17.5% in the quarter to $4.6 billion, while orthopaedics sales grew 2.2% to $2.6 billion. \n</p>\n<p>\n  For the full year 2025, the company posted sales of $25.1 billion, up 11.2% from the year prior. \n</p>\n<p>\n  In 2026, Stryker expects full year organic net sales growth to be in the range of 8% to 9.5% and adjusted earnings to be in the range of $14.90 to $15.10 per share. \n</p>\n<p>\n  Analysts polled by FactSet are predicting 2026 adjusted earnings of $14.03 per share. \n</p>\n<p>\n  \"Having surpassed $25 billion in revenue, we enter 2026 with significant momentum and are poised to continue delivering growth at the high end of MedTech,\" Chief Executive Officer Kevin A. Lobo said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 16:50 ET (21:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stryker Logs Higher 4Q Profit On Sales Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStryker Logs Higher 4Q Profit On Sales Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-30 05:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Stryker posted higher profit in its fourth quarter, boosted by double-digit growth in medical and surgical equipment and neurotechnology sales. \n</p>\n<p>\n  The Portage, Mich.-based, medical supplies maker logged fourth-quarter profit of $849 million, or $2.20 per share, compared with $546 million, or $1.41 per share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at $4.47 per share. Analysts polled by FactSet were expecting $4.06 per share. \n</p>\n<p>\n  Sales rose 11.4% to $7.17 billion, beating the $7.12 billion expected by Wall Street, according to FactSet. Organic sales increased 11% in the period, the company added. \n</p>\n<p>\n  MedSurg and neurotechnology sales increased 17.5% in the quarter to $4.6 billion, while orthopaedics sales grew 2.2% to $2.6 billion. \n</p>\n<p>\n  For the full year 2025, the company posted sales of $25.1 billion, up 11.2% from the year prior. \n</p>\n<p>\n  In 2026, Stryker expects full year organic net sales growth to be in the range of 8% to 9.5% and adjusted earnings to be in the range of $14.90 to $15.10 per share. \n</p>\n<p>\n  Analysts polled by FactSet are predicting 2026 adjusted earnings of $14.03 per share. \n</p>\n<p>\n  \"Having surpassed $25 billion in revenue, we enter 2026 with significant momentum and are poised to continue delivering growth at the high end of MedTech,\" Chief Executive Officer Kevin A. Lobo said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 16:50 ET (21:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYK","symbol_name":"史赛克","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2607054843","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607054843","pubTimestamp":1769723400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Stryker posted higher profit in its fourth quarter, boosted by double-digit growth in medical and surgical equipment and neurotechnology sales.The Portage, Mich.-based, medical supplies maker logged fourth-quarter profit of $849 million, or $2.20 per share, compared with $546 million, or $1.41 per share, a year earlier.Adjusted earnings came in at $4.47 per share. Analysts polled by FactSet were expecting $4.06 per share.Sales rose 11.4% to $7.17 billion, beating the $7.12 billion expected by Wall Street, according to FactSet. Organic sales increased 11% in the period, the company added.MedSurg and neurotechnology sales increased 17.5% in the quarter to $4.6 billion, while orthopaedics sales grew 2.2% to $2.6 billion.For the full year 2025, the company posted sales of $25.1 billion, up 11.2% from the year prior.In 2026, Stryker expects full year organic net sales growth to be in the range of 8% to 9.5% and adjusted earnings to be in the range of $14.90 to $15.10 per share.\"Having surpa","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SYK":"史赛克"},"translate_title":"史赛克第四季度利润因销售增长而增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1.5},"content_text":"By Amira McKee \n\n\n \n\n\n  Stryker posted higher profit in its fourth quarter, boosted by double-digit growth in medical and surgical equipment and neurotechnology sales. \n\n\n  The Portage, Mich.-based, medical supplies maker logged fourth-quarter profit of $849 million, or $2.20 per share, compared with $546 million, or $1.41 per share, a year earlier. \n\n\n  Adjusted earnings came in at $4.47 per share. Analysts polled by FactSet were expecting $4.06 per share. \n\n\n  Sales rose 11.4% to $7.17 billion, beating the $7.12 billion expected by Wall Street, according to FactSet. Organic sales increased 11% in the period, the company added. \n\n\n  MedSurg and neurotechnology sales increased 17.5% in the quarter to $4.6 billion, while orthopaedics sales grew 2.2% to $2.6 billion. \n\n\n  For the full year 2025, the company posted sales of $25.1 billion, up 11.2% from the year prior. \n\n\n  In 2026, Stryker expects full year organic net sales growth to be in the range of 8% to 9.5% and adjusted earnings to be in the range of $14.90 to $15.10 per share. \n\n\n  Analysts polled by FactSet are predicting 2026 adjusted earnings of $14.03 per share. \n\n\n  \"Having surpassed $25 billion in revenue, we enter 2026 with significant momentum and are poised to continue delivering growth at the high end of MedTech,\" Chief Executive Officer Kevin A. Lobo said. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 16:50 ET (21:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}